# Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma

> **NCT04736914** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 47 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** R-CHOP/R-DHAOx； Zanubrutib（induction）； ASCT conditioning ； Zanubrutinib（Maintenance）

## Key facts

- **NCT ID:** NCT04736914
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-31
- **Primary completion:** 2023-01-31
- **Final completion:** 2026-02-28
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2021-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04736914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04736914, "Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04736914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*